부산대학교 도서관

To link to full-text access for this article, visit this link: http://dx.doi.org/10.1016/j.jviromet.2009.01.021 Byline: Eleana Pozzi (a), Valeria Basavecchia (a), Carlo Zanotto (a), Sole Pacchioni (a), Carlo De Giuli Morghen (a)(c), Antonia Radaelli (b)(c) Keywords: Recombinant vaccines; Fowlpox virus; HPV-16; E6/E7 oncoproteins Abstract: Human papilloma virus (HPV)-16 is the most prevalent high-risk mucosal genotype and the expression of the E6 and E7 proteins, which can bind to the p53 and p105Rb host cell-cycle regulatory proteins, is related to its tumorigenicity. Virus-like-particle (VLP)-based immunogens developed recently are successful as prophylactic HPV vaccines. However, given the high number of individuals infected already with HPV and the absence of expression of the L1 structural protein in HPV-infected or HPV-transformed cells, an efficient therapeutic vaccine targeting the non-structural E6 and E7 oncoproteins is required. In this study, two new fowlpox virus (FPV) recombinants encoding the HPV-16 E6 and E7 proteins were engineered and evaluated for their correct expression in vitro, with the final aim of developing a therapeutic vaccine against HPV-related cervical tumors. Although vaccinia viruses expressing the HPV-16 and HPV-18 E6 and E7 oncoproteins have already been studied, due to their natural host-range restriction to avian species and their ability to elicit a complete immune response, FPV recombinants may represent efficient and safer vectors also for immunocompromised hosts. The results indicate that FPV recombinants can express correctly the E6 and E7 oncoproteins, and they should represent appropriate vectors for the expression of these oncoproteins in human cells. Author Affiliation: (a) Department of Medical Pharmacology, University of Milan, 20129 Milan, Italy (b) Department of Pharmacological Sciences, University of Milan, 20133 Milan, Italy (c) Cellular and Molecular Pharmacology Section, Institute of Neurosciences, University of Milan, 20129 Milan, Italy Article History: Received 5 August 2008; Revised 16 January 2009; Accepted 22 January 2009